Veradigm Inc.
MDRX · Other OTC · USD
4,75USD
−0,05 (−1,04 %)Stand 9. Nov., 20:51
Kennzahlen
- Eröffnung
- 4,95
- Vortag
- 4,80
- Tagesspanne
- 4,75 – 4,95
- 52 Wochen
- 3,00 – 6,00
- Volumen
- 1191
- Ø Volumen
- 66.629
- Börsenwert
- 517,71 Mio. $
- KGV
- -7,1
- Gewinn je Aktie (TTM)
- 0,43
- Dividendenrendite
- 0,0 %
- Beta
- 0,5
- Nächste Zahlen
- 10. Nov. 2026
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 588,02 Mio. | 577,43 Mio. | 1,5 Mrd. | 1,63 Mrd. | 1,75 Mrd. |
| Herstellungskosten | 279,6 Mio. | 319,27 Mio. | 937,01 Mio. | 1,06 Mrd. | 1,03 Mrd. |
| Bruttogewinn | 308,42 Mio. | 258,15 Mio. | 565,7 Mio. | 574,51 Mio. | 724,54 Mio. |
| Forschung und Entwicklung | 97,89 Mio. | 84,77 Mio. | 206,06 Mio. | 254,51 Mio. | 295,77 Mio. |
| Vertrieb und Verwaltung | 169,2 Mio. | 97,71 Mio. | 389,94 Mio. | 419,77 Mio. | 450,97 Mio. |
| Operatives Ergebnis | −27,1 Mio. | 75,67 Mio. | −57,66 Mio. | −99,69 Mio. | −95,05 Mio. |
| EBITDA | 58,42 Mio. | 243,41 Mio. | 108,97 Mio. | 12,03 Mio. | 171,61 Mio. |
| Nettogewinn | −86,46 Mio. | 134,44 Mio. | 700,41 Mio. | −182,18 Mio. | 363,74 Mio. |
| Gewinn je Aktie (verwässert) | -0,67 | 1,01 | 4,37 | -1,10 | 2,04 |
Umsatz nach Segment
Produkte · FY 2022
- Provider465,93 Mio. $79,24 %
- Payer & Life Sciences122,09 Mio. $20,76 %
Anteil · ggü. Vorjahr (FY 2021)
Regionen · FY 2022
- UNITED STATES588,02 Mio. $100,00 %−58,97 %
Anteil · ggü. Vorjahr (FY 2021)
Bewertung
Letzte 12 Monate
- KGV
- -7,1
- Kurs-Umsatz-Verhältnis
- 0,9
- Kurs-Buchwert-Verhältnis
- 0,6
- PEG
- 0,1
- Bruttomarge
- 52,5 %
- Operative Marge
- −4,6 %
- Nettomarge
- −14,7 %
- Verschuldungsgrad
- 0,2
- EV/EBITDA
- 5,0
- Eigenkapitalrendite
- −7,1 %
- Kapitalrendite (ROIC)
- −0,7 %
- Free-Cashflow-Rendite
- 16,1 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 52,5 % | 44,7 % | 37,6 % | 35,2 % | 41,4 % |
| Operative Marge | −4,6 % | 13,1 % | −3,8 % | −6,1 % | −5,4 % |
| Nettomarge | −14,7 % | 23,3 % | 46,6 % | −11,2 % | 20,8 % |
| KGV | -26,3 | 17,9 | 3,3 | -8,9 | 4,7 |
| Kurs-Umsatz-Verhältnis | 3,9 | 4,4 | 1,5 | 1,0 | 1,0 |
| Kurs-Buchwert-Verhältnis | 2,2 | 1,8 | 1,4 | 1,3 | 1,1 |
| Verschuldungsgrad | 0,2 | 0,3 | 0,2 | 0,8 | 0,4 |
| Liquidität 3. Grades | 3,0 | 1,6 | 1,2 | 0,7 | 1,1 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 2,05 Mrd. | 2,74 Mrd. | 2,05 Mrd. | 2,53 Mrd. | 2,19 Mrd. |
| EV/EBITDA | 35,0 | 11,3 | 18,8 | 210,7 | 12,8 |
| Eigenkapitalrendite | −8,5 % | 9,5 % | 42,0 % | −14,2 % | 23,5 % |
| Kapitalrendite (ROIC) | −0,7 % | 3,2 % | −2,6 % | −3,5 % | −2,9 % |
| Free-Cashflow-Rendite | 3,7 % | −3,1 % | −5,4 % | −5,2 % | −3,9 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | +1,8 % | −61,6 % | −8,0 % | −6,7 % | +16,8 % |
| Bruttogewinn | +19,5 % | −54,4 % | −1,5 % | −20,7 % | +14,5 % |
| Operatives Ergebnis | −135,8 % | +231,2 % | +42,2 % | −4,9 % | −861,4 % |
| Nettogewinn | −164,3 % | −80,8 % | +484,5 % | −150,1 % | +285,1 % |
| Gewinn je Aktie | −166,3 % | −76,9 % | +497,3 % | −153,9 % | +287,2 % |
| Freier Cashflow | +206,1 % | +36,6 % | −47,0 % | −27,8 % | −153,8 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 1Stark kaufen
- 15Kaufen
- 24Halten
- 2Verkaufen
- 1Stark verkaufen
Kursziel
16,17
Durchschnitt · +240,42 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 583,2 Mio. | 603,6 Mio. | 629,9 Mio. |
| Umsatz (Tief – Hoch) | 583,2 Mio. – 583,2 Mio. | 603,6 Mio. – 603,6 Mio. | 629,9 Mio. – 629,9 Mio. |
| Gewinn je Aktie (Ø) | 0,30 | 0,43 | 0,53 |
| Gewinn je Aktie (Tief – Hoch) | 0,30 – 0,30 | 0,43 – 0,43 | 0,53 – 0,53 |
| Analysten | 1 | 1 | 1 |
Letzte Änderungen
- Stephens & Co.31. Jan. 2025Equal Weight
- TD Cowen28. Mai 2024Buy
- Deutsche Bank19. März 2024Buy → Hold
- RBC Capital19. Jan. 2024Outperform
- Stephens & Co.14. Nov. 2023Equal Weight
- Stephens & Co.10. Okt. 2023Equal Weight
- Argus Research6. Juli 2023Buy → Hold
- Piper Sandler1. Feb. 2023Overweight → Neutral
Quartalszahlen
Nächste Zahlen: 10. Nov. 2026| Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | März 2025 | Feb. 2025 | Nov. 2024 | Aug. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,17 | 0,07 | 0,05 | 0,07 | 0,07 | 0,31 | 0,21 | 0,17 |
| Gewinn je Aktie · Tatsächlich | 0,22 | 0,09 | 0,05 | 0,07 | 0,06 | 0,19 | 0,27 | 0,22 |
| Abweichung | +33,33 % | +21,43 % | 0,00 % | 0,00 % | −21,43 % | −38,13 % | +32,34 % | +33,33 % |
| Umsatz · Tatsächlich | 152 Mio. | 149,6 Mio. | – | 146,5 Mio. | 146,05 Mio. | 153,31 Mio. | 161,3 Mio. | 152 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 13. Okt. 2008 | 17. Okt. 2008 | 5,23 |
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
- Sacks Jonathan S1. Juni 2026 · director, 10 percent owner: Kauf42.507 Aktien
- STONEHILL CAPITAL MANAGEMENT LLC1. Juni 2026 · director, 10 percent owner: Kauf42.507 Aktien
- Greyenbuhl Christian27. Mai 2026 · officer: Chief Financial OfficerVerkauf0 Aktien
- Jacobson Eric L10. Mai 2026 · officer: SVP Interim General CounselVerkauf1584 Aktien · 4,46
- Jacobson Eric L1. Mai 2026 · officer: SVP Interim General CounselKauf75.000 Aktien
- Syed Tehsin M1. Apr. 2026 · officer: CPTOKauf220.986 Aktien
- Baker Tally1. Apr. 2026 · officer: CHROKauf110.493 Aktien
- Trigg Donald1. Apr. 2026 · director, officer: Chief Executive OfficerKauf552.465 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.
Führung
- Donald D. TriggChief Executive Officer & Director
- Tally BakerChief Human Resources Officer
- Christian GreyenbuhlChief Financial Officer
- Elliot BryantSenior Vice President & General Manager for Classic Client Solutions Business Unit
- Eric JacobsonSenior VP, Interim General Counsel & Corporate Secretary
- John SageSenior Vice President of U.S. Hospitals & Health Systems Sales
- CEO
- Donald D. Trigg
- Mitarbeitende
- 2.300
- Hauptsitz
- Chicago, IL, US
- Sektor
- Healthcare
- Branche
- Medical - Healthcare Information Services
- Börsengang
- 26. Juli 1999
- Website
- veradigm.com
Nachrichten
- Defense World · 27. Okt., 4:20Veradigm (NASDAQ:MDRX) Share Price Crosses Below 200 Day Moving Average – Here’s Why
- Business Wire · 21. Okt., 16:00Veradigm Product Portfolio Achieves HITRUST i1 Certification
- Defense World · 3. Sept., 3:49Veradigm (NASDAQ:MDRX) & Augmedix (OTCMKTS:AUGX) Financial Comparison
- Business Wire · 17. Aug., 8:01Veradigm to Participate in Two Upcoming Investor Conferences
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.